Investigators compare the effects of contraceptive agents containing estradiol valerate plus dienogest, ethinylestradiol plus dienogest, or dienogest alone on the suppression of pituitary and ovarian activity.
Progestin and estrogen content of oral contraceptives (birth control pills) chart.
Oral contraceptive use is associated with a reduced risk for ovarian cancer for BRCA mutation carriers.
Women of reproductive age who currently use hormonal contraceptives are at higher risk for developing glaucoma.
The approval was based on data from two phase 3 studies that evaluated the safety, acceptability, efficacy, and cycle control of Nextstellis in 3725 women aged 16 to 50.
Researchers sought to identify and analyze risk factors for thrombosis in adolescent girls receiving hormonal therapy.
Is the regularity of a woman’s menstrual cycles during her reproductive life a significant and independent predictor for T2D risk?
Increased risk for breast cancer observed, which was seen for up to two years after discontinuation of oral contraceptives
Twirla (levonorgestrel and ethinyl estradiol) transdermal system is now available as a method of contraception for use in women of reproductive potential with a BMI <30kg/m2 for whom a combined hormonal contraceptive is appropriate.
Gemmily contains 24 active capsules containing 1mg of norethindrone acetate and 20mcg of ethinyl estradiol and 4 capsules containing 75mg of ferrous fumarate (nonhormonal placebo).
